Cargando…

Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats

OBJECTIVES: The objective of this study was to evaluate the therapeutic effects of balanitoside in diabetic rats. METHODS: Twenty-five rats were divided into five groups. Rats in groups 2 to 5 were treated with streptozotocin to induce hyperglycemia. In addition, rats in groups 1 and 2 received 1 mL...

Descripción completa

Detalles Bibliográficos
Autores principales: Makena, Wusa, Hamman, Wilson O., Buraimoh, Adebayo A., Dibal, Nathan I., Obaje, Sunday G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taibah University 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695012/
https://www.ncbi.nlm.nih.gov/pubmed/31435355
http://dx.doi.org/10.1016/j.jtumed.2018.01.001
_version_ 1783443948179554304
author Makena, Wusa
Hamman, Wilson O.
Buraimoh, Adebayo A.
Dibal, Nathan I.
Obaje, Sunday G.
author_facet Makena, Wusa
Hamman, Wilson O.
Buraimoh, Adebayo A.
Dibal, Nathan I.
Obaje, Sunday G.
author_sort Makena, Wusa
collection PubMed
description OBJECTIVES: The objective of this study was to evaluate the therapeutic effects of balanitoside in diabetic rats. METHODS: Twenty-five rats were divided into five groups. Rats in groups 2 to 5 were treated with streptozotocin to induce hyperglycemia. In addition, rats in groups 1 and 2 received 1 mL of distilled water, whereas those in groups 3, 4, and 5 received 10 and 20 mg/kg balanitoside and 6 U/kg insulin, respectively, for 14 days. All rats were sacrificed on day 15, blood samples were collected, and serum levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured. The liver was processed for examination under a light microscope. RESULTS: The results showed a significant decrease in liver protein concentrations in diabetic control rats, compared to those in the normal control rats and rats treated with 10 mg/kg balanitoside (p < 0.05). There was no significant difference in ALP levels among all groups. However, a significant increase in ALT and AST levels was observed in the diabetic control rats, compared to those in the normal control rats (p < 0.05). Photomicrographs of the liver of the diabetic control rats showed fat and glycogen droplets, vacuolated nuclei, and loss of cellular boundaries, whereas those of the rats treated with balanitoside or insulin showed a small amount of microvesicular fat droplets and slight infiltration of lymphocytes. CONCLUSION: The findings of this study suggest the therapeutic effects of balanitoside in the liver of diabetic rats.
format Online
Article
Text
id pubmed-6695012
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taibah University
record_format MEDLINE/PubMed
spelling pubmed-66950122019-08-21 Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats Makena, Wusa Hamman, Wilson O. Buraimoh, Adebayo A. Dibal, Nathan I. Obaje, Sunday G. J Taibah Univ Med Sci Brief Communication OBJECTIVES: The objective of this study was to evaluate the therapeutic effects of balanitoside in diabetic rats. METHODS: Twenty-five rats were divided into five groups. Rats in groups 2 to 5 were treated with streptozotocin to induce hyperglycemia. In addition, rats in groups 1 and 2 received 1 mL of distilled water, whereas those in groups 3, 4, and 5 received 10 and 20 mg/kg balanitoside and 6 U/kg insulin, respectively, for 14 days. All rats were sacrificed on day 15, blood samples were collected, and serum levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured. The liver was processed for examination under a light microscope. RESULTS: The results showed a significant decrease in liver protein concentrations in diabetic control rats, compared to those in the normal control rats and rats treated with 10 mg/kg balanitoside (p < 0.05). There was no significant difference in ALP levels among all groups. However, a significant increase in ALT and AST levels was observed in the diabetic control rats, compared to those in the normal control rats (p < 0.05). Photomicrographs of the liver of the diabetic control rats showed fat and glycogen droplets, vacuolated nuclei, and loss of cellular boundaries, whereas those of the rats treated with balanitoside or insulin showed a small amount of microvesicular fat droplets and slight infiltration of lymphocytes. CONCLUSION: The findings of this study suggest the therapeutic effects of balanitoside in the liver of diabetic rats. Taibah University 2018-02-09 /pmc/articles/PMC6695012/ /pubmed/31435355 http://dx.doi.org/10.1016/j.jtumed.2018.01.001 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Communication
Makena, Wusa
Hamman, Wilson O.
Buraimoh, Adebayo A.
Dibal, Nathan I.
Obaje, Sunday G.
Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title_full Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title_fullStr Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title_full_unstemmed Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title_short Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
title_sort therapeutic effects of balanitoside in streptozotocin-induced diabetic rats
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695012/
https://www.ncbi.nlm.nih.gov/pubmed/31435355
http://dx.doi.org/10.1016/j.jtumed.2018.01.001
work_keys_str_mv AT makenawusa therapeuticeffectsofbalanitosideinstreptozotocininduceddiabeticrats
AT hammanwilsono therapeuticeffectsofbalanitosideinstreptozotocininduceddiabeticrats
AT buraimohadebayoa therapeuticeffectsofbalanitosideinstreptozotocininduceddiabeticrats
AT dibalnathani therapeuticeffectsofbalanitosideinstreptozotocininduceddiabeticrats
AT obajesundayg therapeuticeffectsofbalanitosideinstreptozotocininduceddiabeticrats